FDA plans ultra-fast review of three psychedelic drugs following Trump directive

The FDA announced ultra-fast review timelines for three psychedelic drugs, including psilocybin and methylone, following an executive order by the Trump administration to accelerate access to psychedelics for mental health treatments. The move aligns with growing support from Trump allies and Health Secretary Robert F. Kennedy Jr.'s advocacy for psychedelic therapies.